CEMIP and colorectal carcinoma: In the present study, we demonstrated that CEMIP promoted CRC metastasis through activating CDC42/MAPK pathway by enhancing the degradation of GRAF1, and CDC42 inhibitor suppressed CEMIP-mediated CRC metastasis.